ORDERING INFORMATION | REIMBURSEMENT | NEWS AND EVENTS | CONTACT US | BRACCO.COM     SEARCH
BRACCO DIAGNOSTICS INC.
Sign In
​
 

The highest relaxivity, for improved CNS MRI
contrast enhancement.

MultiHance® contrast agent for MRI delivers significantly better contrast
enhancement in diagnostic imaging of CNS lesions. MultiHance
(gadobenate dimeglumine) injection, 529 mg/mL is the first and only
contrast agent approved for CNS MRI in the U.S. with the highest
relaxivity,1,2,3,4 due to a weak and transient interaction with serum proteins.

Higher relaxivity is the ability to shorten proton relaxation times, which
increases signal intensity on T1-weighted MR-images. Greater signal
intensity means better contrast enhancement, which may lead to improved
visualization1,7,8.

Two multicenter, intraindividual double-blind randomized crossover comparative studies (n=157, n=138) have shown that MultiHance provides 25–40% better contrast enhancement for MRI in CNS procedures than Magnevist® (gadopentetate dimeglumine) or OMNISCAN™ (gadodiamide).1,5,6,7 These results were statistically significant, with pvalues < 0.0001.

Click Here to discover the benefits of MultiHance®

*These are representative images from reference
studies, individual results may vary. These images have
been referenced from Maravilla KR, et al. Contrast
enhancement of central nervous system lesions:
multicenter intraindividual crossover comparative study of
two MR contrast agents. Radiology. 2006;240:389-400.

 

 Download full Prescribing Information

  Download Material Safety Data Sheet




 
 
 
 
 

REFERENCES: 1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc. July 2011. 2.Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR. 2008;29:668-73. 3. Pintaske J, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5 and 3 Tesla.Erratum Invest Radiol. 2006;41:213-221. 4. Rohrer M, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. 5. Kirchin MA, et al. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998;33(11):798-809. 6. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenatedimeglumine versus gadodiamide. AJNR. 2008;29:1684-91. 7. Maravilla KR, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240:389-400. 8. Knopp MV, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.           

 FindYour_MRI.png 

 

​​​
.

INDICATIONS AND USAGE
MultiHance is indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.

IMPORTANT SAFETY INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings and Precautions (5.1)]†

Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations ranging from mild to severe. The possibility of a reaction should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

†Please consult full Prescribing Information for MultiHance including boxed WARNING contained within this website.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

All trademarks and registered trademarks are the property of their respective owners.

MultiHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia SpA, Ferentino, Italy.
ProHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany).